DK3113782T3 - Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin - Google Patents

Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin Download PDF

Info

Publication number
DK3113782T3
DK3113782T3 DK15711373.9T DK15711373T DK3113782T3 DK 3113782 T3 DK3113782 T3 DK 3113782T3 DK 15711373 T DK15711373 T DK 15711373T DK 3113782 T3 DK3113782 T3 DK 3113782T3
Authority
DK
Denmark
Prior art keywords
gemcitabine
treatment
methods
drug delivery
delivery systems
Prior art date
Application number
DK15711373.9T
Other languages
Danish (da)
English (en)
Inventor
Dennis Giesing
Karen Daniel
Heejin Lee
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Application granted granted Critical
Publication of DK3113782T3 publication Critical patent/DK3113782T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
DK15711373.9T 2014-03-06 2015-03-06 Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin DK3113782T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
PCT/US2015/019262 WO2015134911A1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (1)

Publication Number Publication Date
DK3113782T3 true DK3113782T3 (da) 2022-10-17

Family

ID=52697553

Family Applications (2)

Application Number Title Priority Date Filing Date
DK22196596.5T DK4124339T3 (da) 2014-03-06 2015-03-06 Lægemiddeltilførselssystemer og fremgangsmåder til behandling af blærecancer med gemcitabin
DK15711373.9T DK3113782T3 (da) 2014-03-06 2015-03-06 Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK22196596.5T DK4124339T3 (da) 2014-03-06 2015-03-06 Lægemiddeltilførselssystemer og fremgangsmåder til behandling af blærecancer med gemcitabin

Country Status (24)

Country Link
US (3) US20150250717A1 (enExample)
EP (2) EP4124339B1 (enExample)
JP (4) JP6901858B2 (enExample)
KR (1) KR102338079B1 (enExample)
CN (2) CN119950539A (enExample)
AU (4) AU2015226901B2 (enExample)
BR (1) BR112016020381A8 (enExample)
CA (1) CA2939979C (enExample)
DK (2) DK4124339T3 (enExample)
ES (1) ES2930435T3 (enExample)
FI (1) FI4124339T3 (enExample)
HR (2) HRP20251264T1 (enExample)
HU (1) HUE060704T2 (enExample)
IL (2) IL247347B2 (enExample)
LT (2) LT4124339T (enExample)
MX (1) MX2016011333A (enExample)
PL (2) PL3113782T3 (enExample)
PT (2) PT3113782T (enExample)
RS (2) RS63675B1 (enExample)
RU (1) RU2694902C1 (enExample)
SG (2) SG11201607342QA (enExample)
SI (1) SI4124339T1 (enExample)
SM (2) SMT202500385T1 (enExample)
WO (1) WO2015134911A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
SMT202500385T1 (it) * 2014-03-06 2025-11-10 Taris Biomedical Llc Sistemi e metodi di erogazione di farmaco per il trattamento del cancro della vescica con gemcitabina
CN118453872A (zh) * 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
JP7391009B2 (ja) 2017-07-25 2023-12-04 タリス バイオメディカル エルエルシー 腫瘍転移を処置する方法
US10792297B2 (en) * 2017-11-08 2020-10-06 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
MX2021001264A (es) 2018-08-01 2021-07-02 Taris Biomedical Llc Métodos para tratar la vejiga hiperactiva con el uso de trospio.
WO2021066175A1 (ja) * 2019-10-03 2021-04-08 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
EP4096686A4 (en) * 2020-01-27 2024-01-10 Isola Therapeutics, Inc. TISSUE DOSAGE FOR LOCAL INTRALUMINAL DRUG ADMINISTRATION
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
AU2003278881A1 (en) * 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
CL2004000696A1 (es) * 2003-03-31 2005-05-20 Alza Corp Bomba osmotica, esta formada por una cubierta cilindrica con una camara que recibe al agente osmotico, un extremo abierto que recibe un tapon semipermeable y un orificio de ventilacion en la pared lateral ubicado proximo al extremo abierto, para disi
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
ES2481454T3 (es) 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
CA2733468C (en) 2008-08-09 2017-12-05 Massachusetts Institute Of Technology Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
CA2765734C (en) 2009-06-26 2016-12-13 Taris Biomedical, Inc. Implantable drug delivery devices and methods of making the same
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
LT2512581T (lt) 2009-12-17 2021-03-25 Taris Biomedical Llc Intravezikalinio suderinamumo implantuojamas medicininis įtaisas
ES2732150T3 (es) * 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
RU2598057C2 (ru) 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
BR112015004110A2 (pt) * 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
KR102398262B1 (ko) * 2013-03-15 2022-05-13 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치 및 방법
EP2968120A1 (en) 2013-03-15 2016-01-20 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
KR102385603B1 (ko) * 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
US20160279399A1 (en) * 2013-11-05 2016-09-29 Taris Biomedical Llc Osmotic drug delivery devices, kits, and methods
SMT202500385T1 (it) * 2014-03-06 2025-11-10 Taris Biomedical Llc Sistemi e metodi di erogazione di farmaco per il trattamento del cancro della vescica con gemcitabina

Also Published As

Publication number Publication date
CN119950539A (zh) 2025-05-09
DK4124339T3 (da) 2025-10-13
PL3113782T3 (pl) 2023-01-23
HRP20221252T1 (hr) 2022-12-09
EP4124339A1 (en) 2023-02-01
AU2020217383B2 (en) 2022-09-08
AU2024259822A1 (en) 2024-11-28
RS67337B1 (sr) 2025-11-28
PT3113782T (pt) 2023-01-05
RU2694902C1 (ru) 2019-07-18
BR112016020381A8 (pt) 2018-05-02
SG10202101978SA (en) 2021-04-29
PL4124339T3 (pl) 2025-11-17
CA2939979A1 (en) 2015-09-11
JP6901858B2 (ja) 2021-07-14
BR112016020381A2 (pt) 2017-08-15
SMT202500385T1 (it) 2025-11-10
SG11201607342QA (en) 2016-10-28
JP2024009034A (ja) 2024-01-19
IL311410A (en) 2024-05-01
KR102338079B1 (ko) 2021-12-09
AU2015226901A1 (en) 2016-09-01
JP7383681B2 (ja) 2023-11-20
AU2022215156B2 (en) 2024-09-05
IL311410B1 (en) 2025-07-01
LT4124339T (lt) 2025-11-10
HUE060704T2 (hu) 2023-04-28
IL311410B2 (en) 2025-11-01
US20220117886A1 (en) 2022-04-21
JP2017508749A (ja) 2017-03-30
AU2020217383A1 (en) 2020-09-03
CN106102751A (zh) 2016-11-09
SMT202200449T1 (it) 2023-01-13
HRP20251264T1 (hr) 2025-12-05
SI4124339T1 (sl) 2025-11-28
RS63675B1 (sr) 2022-11-30
JP7061595B2 (ja) 2022-04-28
NZ723303A (en) 2023-10-27
ES2930435T3 (es) 2022-12-13
EP4124339B1 (en) 2025-09-10
AU2022215156A1 (en) 2022-09-01
LT3113782T (lt) 2022-11-25
US20220347091A1 (en) 2022-11-03
JP2022022235A (ja) 2022-02-03
WO2015134911A1 (en) 2015-09-11
PT4124339T (pt) 2025-11-04
CA2939979C (en) 2023-03-21
EP3113782A1 (en) 2017-01-11
JP2019218410A (ja) 2019-12-26
KR20160124425A (ko) 2016-10-27
IL247347B1 (en) 2024-11-01
MX2016011333A (es) 2016-12-07
AU2015226901B2 (en) 2020-05-14
IL247347A0 (en) 2016-11-30
IL247347B2 (en) 2025-03-01
EP3113782B1 (en) 2022-09-28
FI4124339T3 (fi) 2025-10-17
US20150250717A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
DK3113782T3 (da) Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin
EP3558424A4 (en) DRUG DELIVERY SYSTEMS AND METHODS
IL248730A0 (en) Drug delivery system and method of use
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3265043T3 (da) Hjælpemiddel til patienttransport og -træning
DK2943192T3 (da) Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
DK3139986T3 (da) System til administration af terapeutisk gas
DK3244946T3 (da) Infusionsindretningssystem og anordning
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
SG11201608483PA (en) Drug delivery systems and related methods of use
DK3193978T3 (da) Lægemiddelinjektor af hudplastertypen til voluminøs bolus med medikamentforvarmning
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3204085T3 (da) Hus og lægemiddeladministrationsanordning hermed
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3157532T3 (da) Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet
DK3349641T3 (da) Adapter og samling til indførsel af midler i blæren gennem urinrøret uden kateter